
In today’s briefing:
- SGX FTSE Taiwan Index Futures – The Most Liquid Taiwan Offshore Contract
- Will the Approval of Genuine Biotech’s COVID-19 Oral Drug Change China’s Zero-COVID Policy?
SGX FTSE Taiwan Index Futures – The Most Liquid Taiwan Offshore Contract
- The SGX FTSE Taiwan Index Futures are CFTC certified and started trading on 20 July 2020 and use the FTSE Taiwan RIC Capped Index as the underlying.
- Volumes on the SGX FTSE Taiwan Index Futures have increased significantly since launch and the ADTV for July was US$3.34bn versus US$509m for the MSCI Taiwan Index Futures.
- At US$4.86bn, open interest for the SGX FTSE Taiwan Index Futures is also substantially higher than the open interest on the MSCI Taiwan futures at US$797m.
Will the Approval of Genuine Biotech’s COVID-19 Oral Drug Change China’s Zero-COVID Policy?
- China approved the first self-developed COVID-19 oral drug (Azivudine), but there are controversies about efficacy and safety profile on it, which could increase the unpredictability of domestic innovative drugs approval.
- Due to the VBP, fierce competition, uncertainties in the COVID-19 prevention/control policies and decreasing demand, the commercialization performance and outlook of Azivudine could be lower-then-expected in China and overseas markets.
- The approval of Azivudine wouldn’t change the zero-COVID policy. Until President Xi’s third term appointment is confirmed, there’s no reason to expect China to deviate from this policy.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars